Nonablative 1550-nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled pilot study.

PubWeight™: 0.90‹?›

🔗 View Article (PMID 21255869)

Published in J Am Acad Dermatol on January 20, 2011

Authors

Marije W Kroon1, Bas S Wind, Johan F Beek, J P Wietze van der Veen, Ludmila Nieuweboer-Krobotová, Jan D Bos, Albert Wolkerstorfer

Author Affiliations

1: The Netherlands Institute for Pigment Disorders, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. m.w.kroon@amc.uva.nl

Associated clinical trials:

NCT84133969

Articles by these authors

In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol (2006) 2.44

Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med (2003) 2.12

Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc (2004) 1.95

Redarkening of port-wine stains 10 years after pulsed-dye-laser treatment. N Engl J Med (2007) 1.92

How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. J Invest Dermatol (2009) 1.87

The suitability of quality-of-life questionnaires for psoriasis research: a systematic literature review. Arch Dermatol (2002) 1.84

Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet (2012) 1.81

Extent and clinical consequences of antibody formation against adalimumab in patients with plaque psoriasis. Arch Dermatol (2010) 1.77

Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis. PLoS One (2010) 1.73

Skin-depigmenting agent monobenzone induces potent T-cell autoimmunity toward pigmented cells by tyrosinase haptenation and melanosome autophagy. J Invest Dermatol (2011) 1.71

Altered penetration of polyethylene glycols into uninvolved skin of atopic dermatitis patients. J Invest Dermatol (2006) 1.62

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

Loss of TLR2, TLR4, and TLR5 on Langerhans cells abolishes bacterial recognition. J Immunol (2007) 1.55

Formation of fibrosis after nonablative and ablative fractional laser therapy. Dermatol Surg (2011) 1.41

UVB 311 nm tolerance of vitiligo skin increases with skin photo type. Acta Derm Venereol (2005) 1.40

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum (2002) 1.22

Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 1.22

An overview of clinical and experimental treatment modalities for port wine stains. J Am Acad Dermatol (2012) 1.16

Fibroblasts derived from chronic diabetic ulcers differ in their response to stimulation with EGF, IGF-I, bFGF and PDGF-AB compared to controls. Eur J Cell Biol (2002) 1.14

Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. Arthritis Res Ther (2004) 1.09

The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol (2009) 1.07

Mitochondrial PO2 measured by delayed fluorescence of endogenous protoporphyrin IX. Nat Methods (2006) 1.07

Overview of psoriasis. Dermatol Ther (2004) 1.04

Skin barrier function in healthy subjects and patients with atopic dermatitis in relation to filaggrin loss-of-function mutations. J Invest Dermatol (2010) 1.04

In vivo mitochondrial oxygen tension measured by a delayed fluorescence lifetime technique. Biophys J (2008) 1.00

Mitochondrial oxygen tension within the heart. J Mol Cell Cardiol (2009) 1.00

Benzoyl peroxide/clindamycin/UVA is more effective than fluticasone/UVA in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol (2006) 0.97

Towards optimization of selective photothermolysis: prothrombotic pharmaceutical agents as potential adjuvants in laser treatment of port wine stains. A theoretical study. Thromb Haemost (2005) 0.96

Langerhans cells favor skin flora tolerance through limited presentation of bacterial antigens and induction of regulatory T cells. J Invest Dermatol (2013) 0.95

An overview of three promising mechanical, optical, and biochemical engineering approaches to improve selective photothermolysis of refractory port wine stains. Ann Biomed Eng (2011) 0.93

T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res (2011) 0.92

Digital image analysis for the evaluation of the inflammatory infiltrate in psoriasis. Arch Dermatol Res (2005) 0.91

Low systemic exposure after repeated topical application of Pimecrolimus (Elidel), SD Z ASM 981) in patients with atopic dermatitis. Dermatology (2002) 0.90

Increased frequencies of IL-31-producing T cells are found in chronic atopic dermatitis skin. Exp Dermatol (2012) 0.89

The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc (2004) 0.89

Laboratory tests and identified diagnoses in patients with physical and chronic urticaria and angioedema: A systematic review. J Am Acad Dermatol (2003) 0.89

T cells in psoriatic lesional skin that survive conventional therapy with NB-UVB radiation display reduced IFN-gamma expression. Arch Dermatol Res (2004) 0.89

Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res (2004) 0.88

Effective melanoma immunotherapy in mice by the skin-depigmenting agent monobenzone and the adjuvants imiquimod and CpG. PLoS One (2010) 0.88

Clinical differences between atopic and atopiform dermatitis. J Am Acad Dermatol (2008) 0.87

Etanercept: an overview of dermatologic adverse events. Arch Dermatol (2011) 0.87

Modeling acardiac twin pregnancies. Ann N Y Acad Sci (2007) 0.87

Cryoablation induces greater inflammatory and coagulative responses than radiofrequency ablation or laser induced thermotherapy in a rat liver model. Surgery (2009) 0.87

The course of life of patients with childhood atopic dermatitis. Pediatr Dermatol (2009) 0.86

Costs of treatment in patients with moderate to severe plaque psoriasis: economic analysis in a randomized controlled comparison of methotrexate and cyclosporine. Arch Dermatol (2004) 0.86

Validation and refinement of the Millennium Criteria for atopic dermatitis. J Dermatol (2011) 0.86

Expression of terminal complement components by human keratinocytes. Mol Immunol (2007) 0.85

Efficacy and safety of fluticasone propionate 0.005% ointment in the long-term maintenance treatment of children with atopic dermatitis: differences between boys and girls? Pediatr Allergy Immunol (2008) 0.84

Human keratinocytes produce the complement inhibitor factor I: Synthesis is regulated by interferon-gamma. Mol Immunol (2007) 0.83

Ultraviolet B radiation induces a transient appearance of IL-4+ neutrophils, which support the development of Th2 responses. J Immunol (2002) 0.83

High prevalence of autoimmune thyroiditis in children and adolescents with vitiligo. Horm Res Paediatr (2013) 0.83

Non-ablative 1,550 nm fractional laser therapy versus triple topical therapy for the treatment of melasma: a randomized controlled split-face study. Lasers Surg Med (2010) 0.82

Suture-free laser-assisted vessel repair using CO2 laser and liquid albumin solder. J Biomed Opt (2008) 0.82

Wet work and hand eczema in apprentice nurses; part I of a prospective cohort study. Contact Dermatitis (2013) 0.82

Neutrophils infiltrating ultraviolet B-irradiated normal human skin display high IL-10 expression. Arch Dermatol Res (2004) 0.82

Proceedings of the 4th Georg Rajka International Symposium on Atopic Dermatitis, Arcachon, France, September 15-17, 2005. J Allergy Clin Immunol (2006) 0.82

Aberrant function of peripheral blood myeloid and plasmacytoid dendritic cells in atopic dermatitis patients. J Allergy Clin Immunol (2008) 0.82

Postelicitation model of allergic contact dermatitis for predicting the efficacy of topical drugs. Exp Dermatol (2008) 0.82

Expression of the chemokine receptor CCR5 in psoriasis and results of a randomized placebo controlled trial with a CCR5 inhibitor. Arch Dermatol Res (2007) 0.82

Non-ablative 1550 nm fractional laser therapy not effective for erythema dyschromicum perstans and postinflammatory hyperpigmentation: a pilot study. J Dermatolog Treat (2011) 0.82

Human keratinocytes produce the complement inhibitor factor H: synthesis is regulated by interferon-gamma. Mol Immunol (2005) 0.81

Ultraviolet-B irradiation decreases IFN-gamma and increases IL-4 expression in psoriatic lesional skin in situ and in cultured dermal T cells derived from these lesions. Exp Dermatol (2003) 0.81

In situ demonstration of CD40- and CD154-positive cells in psoriatic lesions and keratinocyte production of chemokines by CD40 ligation in vitro. J Pathol (2004) 0.80

Improved quality of life after XeCl excimer transmyocardial laser revascularization: results of a randomized trial. Lasers Surg Med (2003) 0.80

Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol (2002) 0.80

Tertiary teledermatology: a systematic review. Telemed J E Health (2010) 0.80

Transcutaneous laser treatment of leg veins. Lasers Med Sci (2013) 0.80

Ablative fractional laser therapy as treatment for Becker nevus: a randomized controlled pilot study. J Am Acad Dermatol (2011) 0.79

Fluorescent labeling of platelets with polyanionic fluorescein derivatives. Anal Quant Cytol Histol (2009) 0.79

Laser-induced primary and secondary hemostasis dynamics and mechanisms in relation to selective photothermolysis of port wine stains. J Dermatol Sci (2011) 0.79

Expression of IL-20 in synovium and lesional skin of patients with psoriatic arthritis: differential response to alefacept treatment. Arthritis Res Ther (2012) 0.79

Suppression of different phases of systemic contact hypersensitivity by urocanic acid oxidation products. Photochem Photobiol (2004) 0.79

Progressive macular hypomelanosis is associated with a putative Propionibacterium species. J Invest Dermatol (2009) 0.79

Hypertrophy in port-wine stains: prevalence and patient characteristics in a large patient cohort. J Am Acad Dermatol (2012) 0.79

Remission of incapacitating acute cutaneous lupus erythematosus in a patient with systemic lupus erythematosus by B cell-depletive therapy. J Clin Rheumatol (2010) 0.78